The FDA approved benralizumab (Fasenra) for adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

In a clinical trial, nearly 60% of participants achieved remission and 41% fully tapered off oral corticosteroids.

More patients with eosinophilic esophagitis experienced a histologic response with benralizumab (Fasenra) compared with ...

The FDA approved the asthma drug benralizumab (Fasenra) as a new therapy for adults with eosinophilic granulomatosis with ...

AstraZeneca’s Fasenra (benralizumab) met its primary endpoint in the MANDARA trial by demonstrating non-inferiority to the ...

The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...

AstraZeneca has announced that FluMist has been approved in the US as the self-administered influenza vaccine. FluMist, a ...

AstraZeneca PLC (AZN, AZN.L) announced Wednesday that its Fasenra (benralizumab) has been approved in the US for the treatment of ...

AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated ...

AstraZeneca’s FASENRA® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 EGPA is a rare, immune-mediated ...

The FDA has approved Fasenra® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.

More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.